ABOUT LOTTE BIOLOGICS
LOTTE Biologics is a global contract development and manufacturing organization delivering integrated biologics and bioconjugate services across the full product lifecycle. Our capabilities encompass phase-appropriate drug substance manufacturing for mammalian-cell-based biologics, including monoclonal antibodies, fusion proteins, and multispecific modalities, as well as fully integrated Antibody Conjugate manufacturing.
With a unified Dual Hub Service model spanning the United States and South Korea, we strengthen supply chain security, enable scalable manufacturing pathways, and uphold consistent quality across regions.
Our Full Spectrum Services:
- Development Services
- Clinical Manufacturing Services
- Commercial Manufacturing Services
- Antibody Conjugate Manufacturing
- Analytical Services
INDUSTRY INSIGHTS
-
Explore how to choose between single‑use and stainless‑steel bioreactors, outlining key advantages, limitations, and long‑term considerations essential for successful biologics scale‑up.
-
Understand how elite CDMO project management acts as a conductor—integrating molecule expertise, rigorous readiness, and disciplined GMP execution to drive successful biologics manufacturing programs.
-
Accelerate the development of next-generation cancer therapies with optimized ADC solutions designed to meet the diverse needs of global clients.
-
Gain expert insights on mitigating risks in global pharmaceutical manufacturing by learning from Joon Chang and Tracey Partington’s decades of industry experience.
CONTACT INFORMATION
LOTTE Biologics
30th Floor, LOTTE World Tower, 300 Olympic-ro
Songpa-Gu, Seoul, 05551
KOREA, REPUBLIC OF
Contact: Nathalie Scott, Global Marketing Team
NEWS
- LOTTE BIOLOGICS Signs Letter Of Intent (LOI) For Strategic Collaboration With U.S.-Based Multinational Company That Has Also Presence And Operation In Japan And Taiwan
- LOTTE BIOLOGICS Signs Strategic Partnership Agreement With U.S.-Based Asimov
- Rakuten Medical And LOTTE Biologics Sign Manufacturing Agreement To Support Biopharmaceuticals In Global Oncology Program
- LOTTE BIOLOGICS Establishes Contract Manufacturing Partnership With A Leading U.S. Biopharmaceutical Company
- LOTTE BIOLOGICS Signs Antibody Manufacturing Contract With Ottimo Pharma
- LOTTE BIOLOGICS Begins Full-Scale Operation Of ADC Manufacturing Facility
FEATURED BROCHURES
-
This message highlights a CDMO site’s commitment to quality, safety, excellence, experienced staff, stable workforce, and seamless clinical‑to‑commercial transfer to support client success.
-
A U.S.‑based bio manufacturing campus offering end‑to‑end biologics and bioconjugation support with expert teams, scalable capacity, regulatory experience, and flexible solutions from early phase to commercial.
-
Partner with a premier global CDMO to move from discovery to commercialization faster, powered by dual-site manufacturing, 20+ years of expertise, and advanced ADC conjugation.